Landmark Trial for Personalized Medicine Coming Soon: NGS Approval May Be One Offshoot of Lung Cancer “Master Protocol”
This article was originally published in RPM Report
A Friends of Cancer Research/Brookings proposal for a multi-drug, multi-sponsor registrational study of targeted cancer drugs is moving forward. Squamous cell lung cancer will be the initial indication. If successful, the study could lead to rapid final development of several targeted therapies, a potential route to FDA approval of NextGen Sequencing in oncology—and broad adoption of the “master protocol” model.